Cytosorbents (CTSO) Short term Debt (2016 - 2026)

Cytosorbents (CTSO) posted Short term Debt of $6.6 million for Q1 2026, up 165.84% on a QoQ basis from $2.5 million in Q1 2024.

Cytosorbents (CTSO) Short term Debt (2016 - 2026) Analysis & Trends

Cytosorbents' Short term Debt history runs 8 years deep, the most recent figure standing at $6.6 million for Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (changed N/A YoY) and the FY2023 annual result came in at $2.5 million, changed N/A from the prior year.
Short term Debt was $6.6 million for Q1 2026 at Cytosorbents, up from $2.5 million in the prior quarter.
Across five years, Short term Debt topped out at $6.6 million in Q1 2026 and bottomed at $833333.0 in Q3 2023.
A 3-year average of $3.1 million and a median of $2.5 million in 2023 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Cytosorbents	22.58 Mn	17.78 Mn	6.13 Mn

Download Data